The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.

Company Guidance -

Q4 2025

During the Telix Half Quarter 2025 Results and Investor Webcast, the company provided a detailed financial and operational performance overview for the first half of 2025. Telix reported a strong revenue growth of 63% year-on-year, with group revenues reaching $390 million, primarily driven by Illuccix and new third-party revenues from the RLS acquisition. The Precision Medicine business saw a revenue increase of 30% year-on-year, with EBITDA improving by 24%. Overall gross margin was reported at 53%, reflecting a mix of stable margins from Illuccix and contributions from RLS. The company made significant investments in global manufacturing infrastructure, increasing R&D spending by 47% compared to the previous year. Cash on hand was $207 million at the end of the half-year. Telix reaffirmed its full-year guidance, expecting revenues between $770 million and $800 million and an R&D investment increase of 20% to 25%. The company emphasized its strategic focus on long-term asset value and highlighted its progress in expanding its product offerings, geographic presence, and indications in the Precision Medicine and Therapeutics businesses.

Record Revenue Growth

Telix reported a 63% year-on-year increase in group revenues for the first half of 2025, with revenues reaching $390 million.

Successful Product Expansion

The company has expanded its product line to include multiple approved products, with a significant rollout of Illuccix across Europe and upcoming launches of Zircaix and Pixclara.

Strong Precision Medicine Performance

Precision medicine revenues increased by 30% year-on-year, with EBITDA improving by 24% and gross margins steady at 64%.

Strategic Acquisitions and Infrastructure Growth

The company's global manufacturing and distribution sites have grown to 38, and its workforce has more than doubled, now exceeding 1,000 employees.

Robust Cash Position

Telix ended the first half of 2025 with $207 million in cash on hand and generated $18 million in operational cash flow.

Pipeline Progress

Significant progress was made in the therapeutics pipeline, including the launch of pivotal trials in prostate cancer and glioblastoma.

Telix Pharmaceuticals (TLPPF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TLPPF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	0.15 / -	0.039	―	―	―
Aug 20, 2025	2025 (Q2)	0.18 / 0.01	0.058	-82.22% (-0.05)
Feb 20, 2025	2024 (Q4)	0.04 / 0.04	0.032	20.00% (<+0.01)
Aug 22, 2024	2024 (Q2)	0.10 / 0.06	-0.029	300.00% (+0.09)
Feb 22, 2024	2023 (Q4)	0.03 / 0.03	-0.015	308.33% (+0.05)
Aug 23, 2023	2023 (Q2)	0.04 / -0.03	-0.148	80.52% (+0.12)
Apr 17, 2023	2023 (Q1)	- / -	-0.109	―
Feb 27, 2023	2022 (Q4)	-0.04 / -0.02	-0.109	85.80% (+0.09)
Oct 19, 2022	2022 (Q3)	- / -	-0.074	―
Aug 17, 2022	2022 (Q2)	-0.07 / -0.15	-0.074	-99.14% (-0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TLPPF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 20, 2025	$10.95	$12.00	+9.59%
Feb 20, 2025	$17.50	$17.85	+2.00%
Aug 22, 2024	$13.90	$13.42	-3.45%
Feb 22, 2024	$7.48	$7.37	-1.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Telix Pharmaceuticals Ltd. (TLPPF) report earnings?

Telix Pharmaceuticals Ltd. (TLPPF) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).

What is Telix Pharmaceuticals Ltd. (TLPPF) earnings time?

Telix Pharmaceuticals Ltd. (TLPPF) earnings time is at Feb 19, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TLPPF EPS forecast?

TLPPF EPS forecast for the fiscal quarter 2025 (Q4) is 0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing